WDR45 BPAN01 c02
The cell line is not validated yet.
ISTEMi011-A
General
Cell Line |
|
hPSCreg name | ISTEMi011-A |
Cite as: | ISTEMi011-A |
Alternative name(s) |
WDR45 BPAN01 c02
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines | No similar lines found. |
Last update | 12th June 2025 |
User feedback | |
Provider |
|
Generator | Institut from Stem cell Therapy and Exploration of Monogenic diseases (ISTEM) |
Owner | Institut from Stem cell Therapy and Exploration of Monogenic diseases (ISTEM) |
Distributors | |
Derivation country | France |
External Databases |
|
BioSamples | SAMEA118244212 |
General Information |
|
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
Sex | female |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
Yes
|
Donor Relations |
|
Other cell lines of this donor | |
External Databases (Donor) |
|
BioSamples | SAMEA118244213 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
If you do not hold the Donor Consent Form, do you know who does? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
* Does consent expressly prevent the derivation of pluripotent stem cells? | No |
* Does consent pertain to a specific research project? | Yes |
Details on restriction to research project | MECAMEDIRARE |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
an academic institution? | Yes |
a public organisation? | Yes |
a non-profit company? | Yes |
a for-profit corporation? | No |
How may genetic information associated with the cell line be accessed? | Open Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | COMITE DE PROTECTION DES PERSONNES SUD MÉDITERRANÉE I |
Approval number | 2019-A02599-48 |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
Source cell origin |
A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.
Synonyms
|
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Sendai virus |
Genes | |
Is reprogramming vector detectable? |
Yes |
Methods used |
RT-PCR
|
Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions
Surface coating | Vitronectin | ||||||
Feeder cells |
No |
||||||
Passage method | Mechanically | ||||||
CO2 Concentration | 5 % | ||||||
Medium |
Other medium:
Base medium: StemMACS™ iPS-Brew Basal Medium XF, human
Main protein source: Serum concentration: % Supplements
|
||||||
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
||||||
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
||||||
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
SSEA-4 |
Yes |
|||||
POU5F1 (OCT-4) |
Yes |
|||||
TRA 1-60 |
Yes |
|||||
TRA 1-81 |
Yes |
|
||||
NANOG |
Yes |
|||||
SSEA-3 |
Yes |
Score:
Marker | Present | Absent |
mCpG | ||
OCT4 |
Morphology pictures
Differentiation Potency
In vitro spontaneous differentiation
Morphology
ISTEMi011-A_aSMA-Bra.tif
aSMA and Brachyury expression
Microbiology / Virus Screening |
|
HIV 1 | Negative |
HIV 2 | Negative |
Hepatitis B | Negative |
Hepatitis C | Negative |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Is there genome-wide genotyping or functional data available? |
Yes
SNP typing array
Found No mutations |
Login to share your feedback, experiences or results with the research community.